Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Dermatologic Clinics|May 3, 2000
Establishing a practical and effective psoriasis treatment centerJ BagelJournal of the American Academy of Dermatology|March 1, 1985
Hemorrhagic bullae associated with Morganella morganii septicemiaJ Bagel, M E GrossmanThe American Journal of Medicine|March 1, 1986
Subcutaneous nodules in Pseudomonas sepsisJ Bagel, M E GrossmanThe British Journal of Dermatology|November 2, 2021
IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitisA S Paller, J K L Tan, J Bagel, et al.Journal of the American Academy of Dermatology|June 19, 1998
Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trialJ Bagel, W T Garland, D Breneman, et al.Journal of the American Academy of Dermatology|November 17, 2001
A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasisA Martin, E Gutierrez, J Muglia, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|July 13, 2021
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysisK Reich, U Mrowietz, A Menter, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 5, 2020
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)J Bagel, A Blauvelt, J Nia, et al.The British Journal of Dermatology|February 15, 2017
Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumabJ Bagel, S Tyring, K C Rice, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|August 9, 2016
Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A)K Callis Duffin, J Bagel, M Bukhalo, et al.Pageof 2